UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Pharmacyclics, Inc. as Deal Looks Likely to Happen

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Pharmacyclics, Inc.

(NASDAQ: PCYC), and raised the price target from $233.00 to $261.00.In the report, Credit Suisse noted, "We are increasing our target price to $261, the agreed purchase price from ABBV, from $233. We believe the probability of the deal closing is very high. PCYC's remarkable rise highlights the power of a truly novel, first-in-class drug to both impact patients and create huge value for shareholders. We view the ABBV deal as rational, creating the leading franchise in CLL and NHL, with potential upside in solid tumors, multiple myeloma, and autoimmune disease. Given all that has been said about the drug, the deal price, and the strategic rationale, we thought it was worthwhile reflecting on some of the champions of this program at PCYC (see page 2 for our thoughts on the deal)."Pharmacyclics, Inc. closed on Thursday at $254.22.